Latest News

Further research is needed to better understand which characteristics may better predict who are more likely to benefit from estrogen-based menopausal hormonal therapy (MHT) for anxiety.

FDA approves belantamab mafodotin-blmf for relapsed or refractory multiple myeloma, enhancing treatment options and survival rates for patients with limited therapies.

If approved, SYD-101 would have been the first FDA-approved treatment for pediatric myopia, offering hope to millions of affected children in the US.

New research highlights the enhanced humoral response in lymphoma survivors receiving two doses of the PCV20 vaccine, emphasizing vaccination's critical role in infection prevention.

Initiatives aim to reduce residents' high rates of depression and increase self-care skills.

New clinical trial results suggest G-CSF as a promising alternative for managing hot flashes in menopausal women, without the risks of traditional therapies.

Clear communication, personalized counseling, and supportive environments help address barriers, empower patients, and enhance outcomes.

Pharmacy students face emotional struggles but require resilience, shared support, and love to move forward.

Research highlights the impact of sleep disturbances and vasomotor symptoms (VMS) on HRQoL in women transitioning to menopausal period, emphasizing the need for effective management.

When administering T-cell–modifying therapies, infections during and after treatment are a serious and pertinent risk.

When treating vasomotor symptoms (VMS), 15- and 20-mg doses of estetrol (E4) did not significantly hinder postmenopausal women’s blood pressure, including those with cardiovascular risks.

Chronic graft-vs-host disease (cGVHD) is the leading cause of late, non-relapse mortality for patients who have undergone an allogeneic hematopoietic stem cell transplant. Axatilimab, which has durable responses and an attractive safety profile, offers a novel mechanism of action for the treatment for patients who have not succeeded with at least 2 prior lines of systemic therapy.

Community pharmacists are especially valuable amid lower interest and staff shortages.

Infectious disease experts provide the latest updates in RSV, pneumococcal disease, whooping cough, and multidrug-resistant tuberculosis.

New research reveals how menopausal hormone therapy impacts cognitive health in postmenopausal women, highlighting the importance of administration routes and estrogen types.

Overdoses remain alarmingly high despite new tools like OTC Naloxone, highlighting persistent barriers to care.

Experts outline innovative approaches to reduce inequities in diagnostic access and optimize patient outcomes.

As psychedelic medicines near approval, pharmacists will become essential guides in safety and education.

From embedded PrEP care to rapid outbreak response logistics, new models are showing how pharmacists can establish successful public health partnerships to enhance patient access and equity.

Elinzanetant was effective in women with low vasomotor symptom (VMS) burden and those with endocrine therapy-caused VMS.

Compared with late postmenopausal women, menopausal hormone therapy (MHT) may influence certain Alzheimer disease-related biomarkers in early postmenopausal women.